Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.32 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.32 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24070603 | 0.83 | ERN1 (0.46) | CES2CES1ALDH1A1ALOX15ERN1 | |
| SCHEMBL4123145 | 0.83 | ERN1 (0.45) | CES2CES1ALOX15ERN1TSHR | |
| SCHEMBL30340118 | 0.83 | ERN1 (0.46) | CES2CES1ALDH1A1ALOX15ERN1 | |
| SCHEMBL10020262 | 0.79 | ALDH1A1 (0.33) | ALDH1A1ALOX15TSHRHTR7 | |
| SCHEMBL4129229 | 0.77 | ERN1 (0.50) | ALDH1A1ALOX15ERN1 | |
| SCHEMBL29470947 | 0.76 | CES2 (0.67) | CES2CES1ALDH1A1ALOX15KCNQ3 | |
| SCHEMBL192962 | 0.76 | CES2 (0.67) | CES2CES1ALDH1A1ALOX15KCNQ3 | |
| SCHEMBL3894872 | 0.74 | RARB (0.33) | ALDH1A1TSHR | |
| SCHEMBL3154375 | 0.74 | CA12 (0.51) | ALDH1A1 | |
| SCHEMBL491580 | 0.73 | NFE2L2 (0.54) | CES2CES1ALDH1A1ERN1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| WO-2007149033-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | CES2 3860/4885CES1 2003/4885S1PR3 396/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | CES2 3860/4885CES1 2003/4885S1PR3 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.